Healthcare systems are strained to the breaking point as our population ages. Farmland is diminishing as the population swells. Climate change is reducing crop yields as more people go hungry every day. Today, and in the decades to come, new solutions must be discovered to provide quality health and food for at least ten billion people.
We feel it is our responsibility to set new benchmarks
Leaps by Bayer is spearheading a movement to make paradigm-shifting advances in the life sciences – targeting the breakthroughs that could fundamentally change the world for the better. Much of what we are aiming to achieve is not yet possible. Setbacks and failures are to be expected in dealing with such ambitious targets.
But with a 150-year history in the life sciences and capabilities across healthcare and agriculture, Bayer is able to see the bigger picture. We feel it is our responsibility to set new benchmarks; to find the courage to begin where others resist; and to drive breakthrough innovation. And we will not do it alone: we will collaborate with the world’s smartest minds in biotech.
Our joint ventures Collaborating with the world’s smartest minds in biotech
The joint venture Casebia represents the first realization of a targeted investment (for five years or longer) in order to tackle the huge challenges Leaps by Bayer has defined. The objective of Casebia is to research curative treatments for several rare human diseases in Hematology/Autoimmune by utilizing CRISPR/Cas-based DNA editing.Learn more
Initial efforts focus on nitrogen fixation to enhance sustainability in agriculture. Researchers will broadly explore application of beneficial microbes to plants for next generation solutions to agriculture’s biggest challenges.Learn more
Century Therapeutics is a Versant Ventures-created company developing allogeneic or off-the-shelf immune cell therapies for cancer. The company emerged from stealth mode in July 2019 with USD 250 million in financing commitments from Leaps by Bayer, Versant and Fujifilm Cellular Dynamics Inc. (FCDI). The proceeds will enable Century to advance multiple programs into the clinic for hematologic and solid malignancies. Century’s foundational technology is built on induced pluripotent stem cells (iPSCs) that have unlimited self-renewing capacity. This enables multiple rounds of cellular engineering to produce master cell banks of modified cells that can be expanded and differentiated into immune effector cells to supply vast amounts of allogeneic, homogeneous therapeutic products and may bring Century closer to the goal to cure or prevent cancer.
eGenesis is a biotechnology company that utilizes breakthrough gene editing technologies for the development of effective human-compatible organs to address the global organ shortage. Their goal is to make available safe and reliable xeno organs, tissues, and cells to patients in need and advance the field of transplantation. eGenesis uses gene-editing tools, such as CRISPR, to directly address the key virology and immunology hurdles that have impeded xenotransplantation to date. eGenesis is advancing an initial product toward the clinic for a kidney transplant, with the longer-term potential of addressing a broader organ recipient population and expanding the applicability of xenotransplantation into other areas such as cell therapy.
With the creation of the joint venture BlueRock Therapeutics (for four years or longer), the focus lies on research around pluripotent stem cell technologies with the defined objective to create breakthrough innovations to cure Parkinson’s and chronic heart failure.Learn more
Khloris Biosciences is a biotechnology startup founded in 2017 developing a novel approach for anti-cancer vaccines using induced pluripotent stem cells (iPSCs) to trigger a robust immune-response involving innate and adaptive immune cells.Learn more
Pyxis Oncology is an immuno-oncology company focused on developing novel therapies to help patients defeat difficult to treat cancers. Built on the ground-breaking research of Cancer Institute at the University of Chicago Medicine, Pyxis is pursuing promising novel targets derived from the latest insights into the tumor microenvironment. Pyxis has generated preclinical data on these targets and is developing a pipeline of novel antibodies with the potential to help new patient populations not currently served by today’s immunotherapies. Leaps by Bayer led the Company’s USD 22 million Series A financing and was joined by additional institutional and strategic investors including Agent Capital, Ipsen and Longwood Fund.Learn more